INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE.
Recently Kevin Price, Host of the nationally syndicated Price of Business Show, interviewed Jeb Ledell.
The Price of Business had the pleasure of speaking to Jeb Ledell, Chief Operating Officer, AVEO Oncology (NASDAQ: AVEO). AVEO (www.aveooncology.com) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
Mr. Ledell was kind enough to spend time with our listeners and provide background on AVEO’s near-term and long-term goals. He emphasized AVEO’s strategy is to focus its resources on the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies.
AVEO’s lead drug, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA for earlier stage kidney cancer in combination with other drugs.
AVEO is also developing Ficlatuzumab a targeted therapy currently being evaluated in squamous cell carcinoma of the head and neck (HNSCC) and metastatic pancreatic ductal cancer (PDAC). AVEO also has numerous partnerships with other pharma companies including Bristol-Myers Squibb, Astra Zeneca, and Merck, among others. Mr. Ledell emphasized AVEO’s desire to identify and secure business development opportunities either through strategic partnerships or acquisitions.
LISTEN TO THE INTERVIEW IN ITS ENTIRETY HERE:
The Price of Business is one of the longest running shows of its kind in the country and is in markets coast to coast. The Host, Kevin Price, is a multi-award winning author, broadcast journalist, and syndicated columnist. Learn more about the show and its digital partners at www.PriceofBusiness.com (scroll down to the bottom of the page).